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Summary The most convincing evidence that a factor such as dietary fat is causally related to breast cancer
would be obtained from a randomised controlled trial in which exposure to dietary fat intake was
systematically varied. A limitation of randomised controlled trials of breast cancer prevention, however, is the
large sample size required to detect plausible reductions in risk resulting from the intervention. We describe
here experience over a period of 9 years with the use of one risk factor for breast cancer as a criterion for
entry to a clinical trial of breast cancer prevention. The risk factor used was the presence of extensive densities
in the breast tissue on mammography, which has been found by several investigators to be strongly associated
with risk of breast cancer. Using this criterion for selection, 1800 subjects of mean age 46 years were enrolled
between 1982 and 1986, and again between 1988 and the present. Throughout this period, the point estimate
of annual invasive cancer incidence was approximately 6 per 1000 per year. The observed cancer incidence has
been consistently 4-5 times the incidence expected from age-specific breast cancer incidence data for women
living in Ontario. These data show that the selection of subjects for a clinical trial of breast cancer prevention
using the criterion of extensive breast parenchymal densities does identify a group at substantially increased
risk of breast cancer. Use of this criterion for the selection of subjects can substantially reduce the sample size
required for a clinical trial of a preventive strategy.
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Breast cancer is a major cause of morbidity and mortality
throughout most of the Western world, and therapeutic pro-
gress against the disease has been slow (Bailar and Smith,
1986). There is, however, epidemiological evidence indicating
that the disease can be prevented (Doll and Peto, 1981).
Wide variations in breast cancer incidence and mortality
between countries, and changes in disease rates in migrants,
clearly indicate that environmental factors play a role in
causing breast cancer, and suggest that reducing exposure to
these factors might lead to a reduction in risk of the disease.
Several environmental factors which might vary between
individuals, such as body weight (London et al., 1989;
Baanders and de Waard, 1992); and consumption of alcohol
(Longnecker et al., 1988), dietary fat (Prentice and Sheppard,
1990; Willett and Stampfer, 1990; Hiller and McMichael
1990; Howe, 1990), fibre (Rose, 1990) and antioxidant
vitamins (Block 1991), have been described as being
associated with breast cancer risk. However, it is not yet
clear that any of these factors is causally related to breast
cancer and there is controversy about the role of several of
them.
The most convincing evidence that an environmental factor
is causally related to breast cancer, and that changing
exposure to it would reduce the risk of breast cancer, would
be obtained from a randomised controlled trial (Prentice et
al., 1988; Boyd et al., 1990a). In such a trial, exposure to the
putative causative factor would be reduced or eliminated (or
increased in the case of fibre and antioxidant vitamins) in a
randomly selected group of women, and these subjects,
together with a control group, observed for the development
of tumours. Trials involving dietary and pharmacological
interventions in the prevention of breast cancer are now in
progress.
A limitation of randomised controlled trials of breast
cancer prevention, however, is the extremely large sample size
required to detect plausible reductions in risk resulting from
the intervention. The sample size of such trials is influenced
by a number of factors, including the expected cancer
incidence in the absence of the intervention, the duration of
the trial and the extent to which the intervention is expected
to reduce risk (Self et al., 1988). For any given postulated
risk reduction and trial duration, the higher the risk of
disease in the control group, the smaller, and less expensive,
will be the trial.
We describe here experience over a period of 9 years with
the use of one risk factor for breast cancer as a criterion for
entry to a clinical trial of breast cancer prevention. The risk
factor used was the presence of extensive densities in the
breast parenchyma on mammography, which has been found
by several investigators to be strongly associated with risk of




After completing work on the relationship of dense breast
parenchyma to breast cancer risk (Boyd et al., 1982a, 1982b),
we began in 1982 to recruit women with mammographic
parenchymal densities in at least 50% of the breast into a
series of trials testing a dietary intervention. Between 1982
and 1986, 295 women with these radiological characteristics
were recruited into pilot studies (Boyd et al., 1988), and in
1988 a randomised clinical trial was started to determine if
breast cancer incidence could be reduced by the dietary
intervention developed in these pilot studies (Boyd et al.,
1990). Recruitment for this trial was expanded, and a total of
2040 subjects have been enrolled to date. The total number
of subjects recruited throughout this period is therefore app-
roximately 2335.
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1995Briefdescription ofthe intervention
All subjects recruited were, after initial assessment, randomly
allocated to receive one of two types of dietary advice. A
group of controls received teaching according to current
government guidelines (Health and Welfare, Canada, 1992).
These provide general advice about healthy eating, but did
not, until 1993, specify a desirable level of dietary fat intake.
The members of this group were not counselled to change
their intake of dietary fat. An intervention group received
teaching and dietary counselling designed to reduce dietary
fat intake to a target level of 15% of total calories. Further
details concerning the intervention and the dietary and other
changes that result from it have been given elsewhere (Boyd
et al., 1988a,b, 1990b, 1992).
Follow-up
Subjects enrolled between 1982 and 1986 took part in pilot
studies of 12-24 months' duration. Since 1986 all subjects
who participated in these pilot studies have been contacted
annually and asked to respond to a short questionnaire
about breast biopsies during the previous 12 months. Sub-
jects entered into the cancer prevention trial since 1988 have
been asked to respond to the same questionnaire admin-
istered at the clinic visit closest to the anniversary of the date
of randomisation. Subjects who drop out of the trial by no
longer attending clinic visits are contacted annually by mail
and/or telephone. For those who report having had breast
biopsies, permission is sought to obtain pathology reports
and histological slides from the hospitals concerned. In addi-
tion to contacting all of those in the cancer prevention trial,
we have been successful in contacting annually 95% of the
295 subjects from pilot studies and 90% of the subjects who




population of subjects described in Table I and includes all
members of both intervention and control groups combined
as it is too early in the trial to consider an analysis according
to randomisation. The cumulative invasive cancer incidence
has been calculated on 1 January for each of the years
shown, and the point estimates of risk, calculated as an
annual rate per 1000 person-years of observation, and the
associated 95% confidence intervals calculated. Also, at each
time period, we have calculated the annual incidence of
invasive breast cancer expected based upon the age distribu-
tion of the trial population, the length of the period of
observation, and age-specific rates for the Ontario popula-
tion. The expected rates for each time interval are shown in
the figures as asterisks.
From 1986, when cancer risk was first calculated for sub-
jects enrolled in pilot studies, to 1995, the point estimate of
cancer risk is approximately 6 per 1000 per year. At each of
these intervals the observed cancer incidence exceeds the
incidence expected in the population of Ontario. The
incidence observed has been consistently 4-5 times the
incidence expected from age-specific breast cancer incidence
data for women living in Ontario. Estimates of risk from
subjects in both the pilot studies and the main cancer preven-
tion trial, over the entire period of observation, are identical













Table I shows selected characteristics separately for subjects
enrolled between 1982 and 1986, and since 1988. Subjects in
these two time periods are similar with respect to height,
mean age at first pregnancy and marital status. A family
history of breast cancer in at least one first-degree relative
was found in just under 20% of the subjects in both groups.
The subjects enrolled since 1988 were more often parous and
had slightly more children. They also were somewhat heavier
and approximately 2 years older. These differences reflect the
expansion of the sample population from Toronto to smaller
cities, London, Windsor and Hamilton, and from diagnostic
clinics to screening centres.
Cancer risk
Figure 1 shows the cumulative incidence of invasive cancer
(i.e. cancers developing after randomisation) in the total
Table I Selected characteristics of study participants
Characteristics 1982-86 1988 to present P-value"
Number 295 2,003
Mean age (years) 43.8 46.0 <0.01
Mean height (cm) 163.2 163.2 0.99
Mean weight (kg) 59.6 62.8 <0.01
Premenopausal (%) 76.9 74.1 0.30
Post-menopausal (%) 23.1 25.9
Mean age at first pregnancy 25.1 25.6 0.18
Parous (%) 63.9 71.8 0.01
Mean number of children 1.4 1.6 0.01
First-degree relatives with 18.4 18.9 0.82
breast cancer (%)
aContinuous variables compared using t-tests; category variables
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Figure 1 (a) Cancer risk per 1000 person-years. (b) Cancer risk per
1000 person-years excluding cancer in the first 12 months. (c)
Cancer risk per 1000 person-years excluding cancer in the first 24
months.
.
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Table II Observed and expected risk of breast cancer according to
year
Year PY Cancers Obs 95% CI Exp Obs/Exp
1986 688 4 5.81 2.18-15.48 1.29 4.5
1987 977 6 6.14 2.76-13.67 1.31 4.69
1988 1272 7 5.5 2.62-11.54 1.34 4.1
1989 1617 9 5.56 2.82-10.69 1.36 4.09
1990 2139 14 6.55 3.9-11.06 1.39 4.71
1991 2845 17 5.98 3.72-9.62 1.41 4.24
1992 3771 23 6.1 4.05-9.18 1.43 4.27
1993 5143 31 6.02 4.23-8.54 1.45 4.15
1994 7004 36 5.14 3.71-7.14 1.47 3.5
1995 9174 45 4.9 3.66-6.56 1.5 3.27
PY, person-years; Obs, observed cancer incidence per 1000 PY;
Exp, expected cancer incidence per 1000 PY.
To examine the possibility that the 'masking' of breast
cancer by dense breast parenchyma at the time of entry
contributed to the increased cancer incidence observed (Egan
and Mosteller, 1977; Whitehead et al., 1985; Ma et al., 1992),
we recalculated cancer risk for each interval after first exc-
luding all cancers occurring within 12 months, and then
within 24 months, of randomisation. The results shown in
Figure 1 show an annual risk that is essentially the same as
those shown before exclusions in Figure 1, although the
confidence intervals are of course wider.
Discussion
These data show that the selection of subjects for a clinical
trial of breast cancer prevention using the criterion of exten-
sive breast parenchymal densities does identify a group at
substantially increased risk of breast cancer. The risk
experienced by this group is approximately 4-5 times that of
the general population of the same age and has now been
observed consistently over a period of 9 years. The 95%
confidence interval associated with the most recent estimate
of risk shows that we can now exclude a risk lower than 2.9
times that of the age-specific rate for the population. The
results do not appear to be explained, or even influenced, by
'masking' (Egan and Mosteller, 1977; Whitehead et al., 1985;
Ma et al., 1992), that is the presence of undetected cancer at
the time of recruitment.
These findings are consistent with other epidemiological
data showing that extensive mammographic densities are a
risk factor for the development of breast cancer (Saftlas and
Szklo, 1987; Oza and Boyd, 1993). This evidence has been
comprehensively reviewed and shows that most well-
conducted epidemiological studies, both cohort and
case-control in design, have found an association between
mammographically dense breast tissue and increased risk of
breast cancer. Various methods have been used in the
literature for classifying these appearances of breast densities.
In examining the effect that the method of classification has
on the estimation of cancer risk, we have found quantitative
methods that attempt to determine the proportion of the
breast occupied by densities generate the highest estimates of
risk (Warner et al., 1992). Similar quantitative methods were
used to select the subjects described here, and the risk
observed is consistent with the high risks predicted from the
other papers describing the use of quantitative methods to
predict risk (Boyd et at., 1982b; Brisson et at., 1982, 1984;
Wolfe et at., 1987; Saftias et at., 1989, 1991).
It is, however, possible that other factors associated with
the willingness of subjects to enter a trial of cancer preven-
tion may also have influenced the observed breast cancer
risk. The high prevalence of subjects with at least one first-
degree relative with breast cancer is one identifiable feature
in subjects who entered the trial that may have contributed
to the increased risk observed. However, any contribution of
this feature to the cancer risk in the present population is
likely to be small (Kelsey, 1993).
These findings indicate that the strategy used here to select
subjects for a trial of breast cancer prevention can substan-
tially increase the number of cancers expected, and reduce
the number of subjects required, compared with a trial that
enrols members of the general population of the same age,
thus making cancer prevention studies feasible. The fre-
quency of extensive mammographic densities varies with the
age of the population examined, but approximately 20% of
the participants in the Canadian National Breast Screening
Trial, a randomised trial of mammographic screening in
women aged 40-59, had more than 50% of the breast
occupied by mammographic densities and would have been
eligible for this cancer prevention trial.
We have used the statistical procedure described by Self et
al. (1988) to determine the number of subjects required for a
clinical trial of breast cancer prevention, making the same
assumptions about the difference in dietary fat intake
between control and intervention subjects and the extent to
which cancer rates might be influenced by such a fat differen-
tial, but different assumptions about rates of breast cancer in
the control group. We find that a total of 6000 subjects is
required using the estimates of cancer risk described in the
present paper, compared with a total sample size of 26 000 if
age-specific cancer rates for the Ontario population are
used.
The use of a criterion such as mammographic densities for
selecting subjects for breast cancer prevention studies raises
questions about the generalisability of the results to individ-
uals with other mammographic characteristics. We have
found in other studies that mammographic densities in more
than 50% of the breast are present in a substantial propor-
tion of women who develop breast cancer. For example, in
the Canadian National Breast Screening Study, 44% of those
who developed breast cancer had at entry to the trial mam-
mographic densities that would have made them eligible for
our present trial (Boyd et al., 1994). Further, mammographic
densities are a continuous variable that influence risk of
breast cancer throughout the range of measurement, with a
2% increase in the relative risk of breast cancer for each 1%
increase in density (Boyd et al., 1994). Use of the criterion of
50% density in breast tissue as a criterion for trial eligibility
therefore selects subjects in the upper part of a continuum of
risk. There is currently no evidence to indicate that mam-
mographic densities are directly related to diet, or that the
results of dietary change in the group of individuals selected
for the trial described here will differ qualitatively from those
seen in women at average risk of breast cancer. Any result
found in high-risk subjects is likely to apply also to those of
average risk. The extent to which women at average risk of
breast cancer will be prepared to alter their diets is uncertain,
but presumably their willingness to change will be influenced
by the results of trials such as the one described here.
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